Exscientia Ai Ltd., A Wholly Owned Subsidiary Of Recursion Pharmaceuticals, Inc.
Clinical trials sponsored by Exscientia Ai Ltd., A Wholly Owned Subsidiary Of Recursion Pharmaceuticals, Inc., explained in plain language.
-
AI-Designed drug trial opens for Tough-to-Treat cancers
Disease control Recruiting nowThis study is testing a new drug called GTAEXS617 in people with advanced solid tumors that have stopped responding to standard treatments. Researchers want to find the safest dose and see if the drug can shrink tumors in cancers like lung, pancreatic, ovarian, and breast cancer.…
Phase: PHASE1, PHASE2 • Sponsor: Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Apr 02, 2026 14:57 UTC
-
AI-Designed pill enters human testing for tough blood cancers
Disease control Recruiting nowThis is the first human study of an experimental oral drug called EXS73565 for people with advanced B-cell blood cancers that have returned or stopped responding to standard treatments. The main goal is to find a safe dose and understand how the drug behaves in the body, while al…
Phase: PHASE1 • Sponsor: Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC